Maintenance of intestinal epithelial barrier integrity by a combination of probiotics, herbal extract, and vitamins.
Study Design
- 研究タイプ
- In Vitro
- 対象集団
- In vitro (intestinal epithelial cells)
- 介入
- Maintenance of intestinal epithelial barrier integrity by a combination of probiotics, herbal extract, and vitamins. None
- 比較対照
- None
- 主要アウトカム
- Intestinal epithelial barrier integrity
- 効果の方向
- Positive
- バイアスリスク
- Unclear
Abstract
BACKGROUND: Irritable bowel syndrome (IBS) and Inflammatory bowel disease (IBD) are pathological conditions that severely hamper the quality of life of patients. Especially in pediatric and adolescent patients, the use of Complementary and alternative medicine is an appealing approach as an adjuvant for the management of symptoms, limiting the detrimental effect of the conventional therapy. In this work, we tested the effect of Enterokind Junior (EntJ), a mix of two probiotic strains Lactobacillus reuteri DSM 25175 and Lactobacillus acidophilus DSM 24936, Matricaria Chamomilla, and vitamins, in in vitro model of intestinal inflammation. Caco-2 cells were subjected to LPS treatment or THP-1 cells stimulated with LPS treatment, as paradigms of inflammatory conditions. METHODS: The effect of the probiotic formulation was evaluated by measuring Caco-2 monolayer's Transepithelial Electrical resistance (TEER) and paracellular permeability alterations, tight junction proteins expression and localization by confocal microscopy, and release of pro-inflammatory cytokines (TNF-α and IL-8) by ELISA assay. RESULTS: Results demonstrated that upon impairment of intestinal parameters induced by inflammatory stimuli, the combination of probiotic was able to prevent TEER decrease and paracellular permeability alterations and to maintain the tight junction expression and localization. Moreover, the release of proinflammatory cytokines induced by inflammation was reduced by EntJ treatment. CONCLUSIONS: This work, in line with previous observations, supports a protective role of Lactobacillus reuteri DSM 25175, Lactobacillus acidophilus DSM 24936 and the other components in the maintenance of a healthy gut, holding up the use of this combination as an adjuvant for irritable bowel syndrome-related symptoms management.
要約
A protective role is supported in the maintenance of a healthy gut, holding up the use of this combination as an adjuvant for irritable bowel syndrome-related symptoms management.
Used In Evidence Reviews
Similar Papers
Nature medicine · 2007
Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors.
PloS one · 2012
A meta-analysis of probiotic efficacy for gastrointestinal diseases.
Journal of clinical gastroenterology · 2004
Bacteriotherapy using fecal flora: toying with human motions.
Journal of clinical gastroenterology · 2012
The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
Journal of clinical gastroenterology · 2004
Probiotics in the treatment of irritable bowel syndrome.
Journal of gastroenterology and hepatology · 2014